GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Debt-to-Equity
中文

Neuronetics (Neuronetics) Debt-to-Equity : 1.83 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Neuronetics Debt-to-Equity?

Neuronetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.85 Mil. Neuronetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $61.63 Mil. Neuronetics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $34.19 Mil. Neuronetics's debt to equity for the quarter that ended in Dec. 2023 was 1.83.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neuronetics's Debt-to-Equity or its related term are showing as below:

STIM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.15   Med: 0.58   Max: 1.83
Current: 1.83

During the past 8 years, the highest Debt-to-Equity Ratio of Neuronetics was 1.83. The lowest was -0.15. And the median was 0.58.

STIM's Debt-to-Equity is ranked worse than
91.88% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs STIM: 1.83

Neuronetics Debt-to-Equity Historical Data

The historical data trend for Neuronetics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Debt-to-Equity Chart

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial 0.72 1.50 0.46 0.70 1.83

Neuronetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.83 0.88 1.06 1.83

Competitive Comparison of Neuronetics's Debt-to-Equity

For the Diagnostics & Research subindustry, Neuronetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuronetics's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neuronetics's Debt-to-Equity falls into.



Neuronetics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neuronetics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Neuronetics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuronetics  (NAS:STIM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Neuronetics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neuronetics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics (Neuronetics) Business Description

Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Keith J Sullivan director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong officer: CFO C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper director BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook director 162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir director C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley director 2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie officer: Chief Commercial Officer C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355